DEVELOPMENTS IN ANTIEPILEPTIC DRUG-THERAPY

被引:19
作者
WALKER, MC
SANDER, JW
机构
[1] Epilepsy Research Group, University Dept. Clinical Neurology, Institute of Neurology
关键词
D O I
10.1097/00019052-199404000-00009
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Development of new antiepileptic drugs has continued to progress, with both the evolution of new drugs, as well as new formulations of old drugs. It is hoped that, with advances in the understanding of the molecular basis of epilepsy, novel antiepileptic drugs will come about through design rather than serendipity. This article concentrates on a selection of the more promising antiepileptic drugs and reviews their recent progress. Felbamate, lamotrigine, vigabatrin, zonisamide, and gabapentin are already in clinical use in certain countries. Stiripentol and other potential antiepileptic drugs are also reviewed. in addition, there have been strategies to improve the pharmacokinetics of currently used antiepileptic drugs and we have concentrated on controlled-release carbamazepine and oxcarbazepine, both available in certain countries. It is, however, increasingly apparent that good comparative studies are needed before definitive advice can be given in the drug treatment of epilepsy.
引用
收藏
页码:131 / 139
页数:9
相关论文
共 69 条
[51]   DEVELOPMENT OF TOLERANCE TO THE ANTICONVULSANT EFFECT OF VIGABATRIN IN AMYGDALA-KINDLED RATS [J].
RUNDFELDT, C ;
LOSCHER, W .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1992, 213 (03) :351-366
[52]   AN ASSESSMENT OF SERUM AND RED-BLOOD-CELL FOLATE CONCENTRATIONS IN PATIENTS WITH EPILEPSY ON LAMOTRIGINE THERAPY [J].
SANDER, JWAS ;
PATSALOS, PN .
EPILEPSY RESEARCH, 1992, 13 (01) :89-92
[53]   DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY OF LAMOTRIGINE IN TREATMENT-RESISTANT PARTIAL SEIZURES [J].
SCHAPEL, GJ ;
BERAN, RG ;
VAJDA, FJE ;
BERKOVIC, SF ;
MASHFORD, ML ;
DUNAGAN, FM ;
YUEN, WC ;
DAVIES, G .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1993, 56 (05) :448-453
[54]   ZONISAMIDE FOR ADD-ON TREATMENT OF REFRACTORY PARTIAL EPILEPSY - A EUROPEAN DOUBLE-BLIND TRIAL [J].
SCHMIDT, D ;
JACOB, R ;
LOISEAU, P ;
DEISENHAMMER, E ;
KLINGER, D ;
DESPLAND, A ;
EGLI, M ;
BAUER, G ;
STENZEL, E ;
BLANKENHORN, V .
EPILEPSY RESEARCH, 1993, 15 (01) :67-73
[55]  
SCHROEDER CE, 1992, EPILEPSIA, V33, P13
[56]   VIGABATRIN (GAMMA-VINYL-GABA) - NEUROPATHOLOGIC EVALUATION IN 5 PATIENTS [J].
SIVENIUS, J ;
PALJARVI, L ;
VAPALAHTI, M ;
NOUSIAINEN, U ;
RIEKKINEN, PJ .
EPILEPSIA, 1993, 34 (01) :193-196
[57]   OUTCOMES OF ADD-ON TREATMENT WITH LAMOTRIGINE IN PARTIAL EPILEPSY [J].
SMITH, D ;
BAKER, G ;
DAVIES, G ;
DEWEY, M ;
CHADWICK, DW .
EPILEPSIA, 1993, 34 (02) :312-322
[58]   A SATURABLE TRANSPORT MECHANISM IN THE INTESTINAL-ABSORPTION OF GABAPENTIN IS THE UNDERLYING CAUSE OF THE LACK OF PROPORTIONALITY BETWEEN INCREASING DOSE AND DRUG LEVELS IN PLASMA [J].
STEWART, BH ;
KUGLER, AR ;
THOMPSON, PR ;
BOCKBRADER, HN .
PHARMACEUTICAL RESEARCH, 1993, 10 (02) :276-281
[59]   LAMOTRIGINE FOR GENERALIZED EPILEPSIES [J].
STEWART, J ;
HUGHES, E ;
REYNOLDS, EH .
LANCET, 1992, 340 (8829) :1223-1223
[60]  
SUMAN CN, 1993, EUR J PHARMACOL, V244, P293